To study therapeutic efficacy of aripiprazole augmentation in treatment resistant obsessive compulsive disorder

GMC medical college0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Patients of ocd diagnosed as per DSM 5, further treatment resistant OCD defined as patients who have undergone trial of first line therapies that is two different SSRI in adeqaute dose for adequate duration that is 10-12 weeks. patients who did not show adequate response on Ybocs score that is more than 35 % reduction on YBOCS score for full response and more than 25% to 35% reduction for partial response were enrolled ..Aripiprazole was added to ongoing treatment. Group 1 consisted to patients with ongoing treatment plus dose of aripiprazole less than equal to 5mg/day and group 2 consisted dose or aripiprazole more than 5mg to 10mg/day along with ongoing treatment. Response was noted at 2,4,8,12 weeks using YBOCS , CGI. BABS scale was used for assessment of insight and beliefs. GAF and WHOQOL-BREF was used for assessment of quality of life and wellbeing.

•other psychiatric disorder, pregnant females, substance abuse,any other medical illness, other OCRD such as BDD,TTM,Hoarding disorder, and those who refused to give consent.

发起方

GMC medical college